How much has Aidoc raised?
Aidoc has about $370 million reported before the 2026 series e; over $500 million with 2026 financing; the latest public valuation/status marker is Undisclosed.
- Total raised
- About $370 million reported before the 2026 Series E; over $500 million with 2026 financing
- Disclosed rounds
- 5
- Latest round
- Series E
- Latest valuation
- Undisclosed
- First raised
- 2017
- Notable backer
- Goldman Sachs Alternatives
Aidoc's funding rounds
Aidoc's disclosed financing history shows capital raised for product, hiring, and market expansion.
- 2017Seed — $7 millionLead/backers: TLV Partners.
- 2019Series B — $27 millionLead/backers: Square Peg.
- 2021Series C — $66 millionLead/backers: General Catalyst.
- 2022Series D — $110 millionLead/backers: TCV and Alpha Intelligence Capital.
- 2026Series E — $150 million; Valuation undisclosedLead/backers: Goldman Sachs Alternatives.
Sources:Axios Aidoc Series E coverageWikipedia Aidoc summary
How much has Aidoc raised in total?
Aidoc has about $370 million reported before the 2026 series e; over $500 million with 2026 financing based on public reporting. 2017: Seed — $7 million, led/backed by TLV Partners. 2019: Series B — $27 million, led/backed by Square Peg. 2021: Series C — $66 million, led/backed by General Catalyst. 2022: Series D — $110 million, led/backed by TCV and Alpha Intelligence Capital. 2026: Series E — $150 million, led/backed by Goldman Sachs Alternatives (Valuation undisclosed).
Where debt, secondaries, or preferred-equity packages are included in public reporting, they are described as reported rather than converted into common-equity funding.
Who are Aidoc's investors?
The disclosed investor base includes TLV Partners; Square Peg; General Catalyst; TCV and Alpha Intelligence Capital. These investors matter because they indicate whether the company is optimized for venture-scale software growth, capital-intensive deployment, clinical development, or government procurement.
For sellers, investor quality is a useful signal, but procurement timing still depends on budget ownership and integration urgency.
Why did Aidoc's valuation move?
The latest public marker is Undisclosed. Valuation movement appears tied to progress in clinical imaging ai, public customer/partner proof, and the broader investor appetite for AI-enabled category leaders.
No public source confirms profitability, so valuation should be treated as a financing-market signal rather than an operating-margin signal.
Is Aidoc profitable, and will it IPO?
Aidoc has not publicly disclosed audited profitability. IPO timing is not confirmed unless explicitly stated in company or news sources.
The practical read is that the company remains private and is using capital to extend product, hiring, regulatory, deployment, or R&D capacity.
What does Aidoc's funding mean if you sell into them?
The funding profile suggests budget exists for tools tied directly to clinical imaging ai, security, compliance, infrastructure, hiring leverage, and customer deployment. Sellers should map pitches to a funded initiative rather than a generic productivity story.
The best outreach angle is to show how a product shortens deployment time, lowers risk, or improves measurable outcomes for the teams named in the leadership and product sections.
As of June 2026.Sources:Aidoc websiteAxios Aidoc Series E coverageWikipedia Aidoc summary
Aidoc — frequently asked questions
